Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 1/2014

01.02.2014 | editorial

Cure and care for children and adolescents with acute myeloid leukemia in Middle and Eastern European countries: part II

verfasst von: Assoc. Prof. Michael N. Dworzak, MD, PhD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Excerpt

Acute myeloid leukemia (AML), has always been among the most dreadful cancers of childhood and adolescence. Curing this type of leukemia still engages the most intense chemotherapy available in pediatrics, which also contains stem cell transplantation (SCT) in a considerable proportion of cases. …
Literatur
1.
Zurück zum Zitat Creutzig U, Tallen G. Treatment results for children and adolescents with acute myeloid leukemia in middle and eastern European countries. Memo. 2013;6:5–8.CrossRef Creutzig U, Tallen G. Treatment results for children and adolescents with acute myeloid leukemia in middle and eastern European countries. Memo. 2013;6:5–8.CrossRef
2.
Zurück zum Zitat Sramkova L, Sterba J, Hrstkova H, et al. Development of treatment and clinical results in childhood acute myeloid leukemia in the Czech Republic. Memo. 2013;6:41–5.CrossRef Sramkova L, Sterba J, Hrstkova H, et al. Development of treatment and clinical results in childhood acute myeloid leukemia in the Czech Republic. Memo. 2013;6:41–5.CrossRef
3.
Zurück zum Zitat Kolenova A, Bubanska E, Oravkinova I, et al. Development of treatment and clinical results in childhood acute myeloid leukemia in the Slovak Republic. Memo. 2013;6:46–53.CrossRef Kolenova A, Bubanska E, Oravkinova I, et al. Development of treatment and clinical results in childhood acute myeloid leukemia in the Slovak Republic. Memo. 2013;6:46–53.CrossRef
4.
Zurück zum Zitat Balwierz W, Pawinska-Wasikowska K, Klekawka T, et al. Development of treatment and clinical results in childhood acute myeloid leukemia in Poland. Memo. 2013;6:54–62.PubMedCentralPubMedCrossRef Balwierz W, Pawinska-Wasikowska K, Klekawka T, et al. Development of treatment and clinical results in childhood acute myeloid leukemia in Poland. Memo. 2013;6:54–62.PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Krstovski N, Kuzmanovic M, Vujic D, et al. Treatment results of childhood acute myeloid leukemia in Serbia. Memo. 2013;6:63–8.CrossRef Krstovski N, Kuzmanovic M, Vujic D, et al. Treatment results of childhood acute myeloid leukemia in Serbia. Memo. 2013;6:63–8.CrossRef
6.
Zurück zum Zitat Szegedi I, Jakab Z, Masath P, et al. Development of treatment and clinical results in childhood acute myeloid leukemia in Hungary. Memo. 2013;6:69–72.CrossRef Szegedi I, Jakab Z, Masath P, et al. Development of treatment and clinical results in childhood acute myeloid leukemia in Hungary. Memo. 2013;6:69–72.CrossRef
7.
Zurück zum Zitat Boztug H, Mühlegger N, Glogova E, et al. Development of treatment and clinical results in childhood AML in Austria (1993–2013). Memo. 2014;7(1). doi:10.1007/ s12254-014-0135-y. Boztug H, Mühlegger N, Glogova E, et al. Development of treatment and clinical results in childhood AML in Austria (1993–2013). Memo. 2014;7(1). doi:10.1007/ s12254-014-0135-y.
8.
Zurück zum Zitat Polychronopoulou S, Baka M, Servitzoglou M, et al. Treatment and clinical results in childhood AML in Greece. Memo. 2014;7(1). doi:10.1007/s12254-013-0112-x. Polychronopoulou S, Baka M, Servitzoglou M, et al. Treatment and clinical results in childhood AML in Greece. Memo. 2014;7(1). doi:10.1007/s12254-013-0112-x.
9.
Zurück zum Zitat Velikonja O, Stefanović M, Kitanovski L, et al. Development of treatment and clinical results in childhood acute myeloid leukemia in Slovenia in the period from 1991 to 2010. Memo. 2014;7(1). doi:10.1007/s12254-013-0090-z. Velikonja O, Stefanović M, Kitanovski L, et al. Development of treatment and clinical results in childhood acute myeloid leukemia in Slovenia in the period from 1991 to 2010. Memo. 2014;7(1). doi:10.1007/s12254-013-0090-z.
10.
Zurück zum Zitat Creutzig U, Zimmermann M, Dworzak MN, et al. Development of a curative treatment within the AML-BFM studies. Klin Padiatr 2013;225 (Suppl. 1):79–86. Creutzig U, Zimmermann M, Dworzak MN, et al. Development of a curative treatment within the AML-BFM studies. Klin Padiatr 2013;225 (Suppl. 1):79–86.
11.
Zurück zum Zitat Tallen G, Dworzak M, Gadner H, et al. Imperative of continual support by the European community for future advances in paediatric oncology in Europe: meeting report of the EC-funded sciencecommunication project DIRECT “Overcoming Cancer with Research”. Memo. 2009;2:234–45.CrossRef Tallen G, Dworzak M, Gadner H, et al. Imperative of continual support by the European community for future advances in paediatric oncology in Europe: meeting report of the EC-funded sciencecommunication project DIRECT “Overcoming Cancer with Research”. Memo. 2009;2:234–45.CrossRef
12.
Zurück zum Zitat Tu JV, Willison DJ, Silver FL, et al. Impracticability of informed consent in the registry of the Canadian stroke network. N Engl J Med. 2004;350:1414–21.PubMedCrossRef Tu JV, Willison DJ, Silver FL, et al. Impracticability of informed consent in the registry of the Canadian stroke network. N Engl J Med. 2004;350:1414–21.PubMedCrossRef
13.
Zurück zum Zitat Lauer MS, D’Agostino RB. The Randomized registry trial—the next disruptive technology in clinical research? N Engl J Med. 2013;369:1979–81.CrossRef Lauer MS, D’Agostino RB. The Randomized registry trial—the next disruptive technology in clinical research? N Engl J Med. 2013;369:1979–81.CrossRef
14.
Zurück zum Zitat Reith C, Landray M, Devereaux PJ, et al. Randomized clinical trials—removing unnecessary obstacles. N Engl J Med. 2013;369:1061–65.PubMedCrossRef Reith C, Landray M, Devereaux PJ, et al. Randomized clinical trials—removing unnecessary obstacles. N Engl J Med. 2013;369:1061–65.PubMedCrossRef
15.
Zurück zum Zitat Creutzig U, Ritter J, Zimmermann M, et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of study acute myeloid leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol. 2001;19(10):2705–13.PubMed Creutzig U, Ritter J, Zimmermann M, et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of study acute myeloid leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol. 2001;19(10):2705–13.PubMed
16.
Zurück zum Zitat Creutzig U, Ritter J, Zimmermann M, et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group. Leukemia. 2001;15(3):348–54.PubMedCrossRef Creutzig U, Ritter J, Zimmermann M, et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group. Leukemia. 2001;15(3):348–54.PubMedCrossRef
17.
Zurück zum Zitat Creutzig U, Zimmermann M, Bourquin JP, et al. Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). Blood. 2011;118(20):5409–15.PubMedCrossRef Creutzig U, Zimmermann M, Bourquin JP, et al. Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). Blood. 2011;118(20):5409–15.PubMedCrossRef
18.
Zurück zum Zitat Creutzig U, Zimmermann M, Bourquin JP, et al. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from study AML-BFM 2004. Blood. 2013;122(1):37–43.PubMedCrossRef Creutzig U, Zimmermann M, Bourquin JP, et al. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from study AML-BFM 2004. Blood. 2013;122(1):37–43.PubMedCrossRef
19.
Zurück zum Zitat Kaspers GJ, Zimmermann M, Reinhardt D, et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol. 2013;31(5):599–607.PubMedCrossRef Kaspers GJ, Zimmermann M, Reinhardt D, et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol. 2013;31(5):599–607.PubMedCrossRef
Metadaten
Titel
Cure and care for children and adolescents with acute myeloid leukemia in Middle and Eastern European countries: part II
verfasst von
Assoc. Prof. Michael N. Dworzak, MD, PhD
Publikationsdatum
01.02.2014
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2014
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0134-z

Weitere Artikel der Ausgabe 1/2014

memo - Magazine of European Medical Oncology 1/2014 Zur Ausgabe